★ Mitochondrial & Longevity

Cardiogen

Mitochondrial & Longevity · 20mg × 10 vials

Khavinson cardiac bioregulator tetrapeptide (AEDR). Studied for gene-expression effects in aged cardiomyocyte models.

✓ 99%+ Purity ✓ Lab Tested ✓ COA on Request ✓ Discreet Shipping ✓ Direct Support
📋 Certificate of Analysis Request the third-party COA via Telegram
Pricing
$205from · 10-vial kit
Shipping: $40 US · $60 international (10-vial kits only) · single vials $20, US only · free over $1,000
20mg × 10 vials$205
Order / Consult on Telegram →
short (free tetrapeptide cleared within minutes to hours; downstream cardiomyocyte gene-expression and tissue effects persist months)
Half-life
metabolic-longevity
Class
Overview

What Is Cardiogen?

Cardiogen is the Khavinson cardiac bioregulator: the synthetic tetrapeptide Ala-Glu-Asp-Arg (AEDR), modelled on the active fraction of the polypeptide complex originally extracted from bovine cardiac tissue at the St Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. It belongs to the Khavinson short-peptide series alongside Epithalon (AEDG, pineal), Vilon (KE, immune), Thymogen (EW, immune), Cartalax (AED, cartilage), Livagen (KEDA, liver), Bronchogen (AEDL, bronchopulmonary), and Testagen (KEDG, testes).

The proposed mechanism follows the Khavinson bioregulator paradigm: tissue-targeted short peptides that bind regulatory regions of DNA in their target cell population. The group's molecular work describes direct interaction of these peptides with histone-bound chromatin and promoter sequences of tissue-specific genes, shifting gene expression in cardiomyocytes and surrounding cardiac tissue toward a younger pattern. Published Khavinson-group work in aged-rat cardiac tissue and isolated cardiomyocyte models reports restored expression of contractile-protein genes (a myosin heavy chain isoform shift back toward alpha-MHC from the senescent beta-MHC pattern), normalised calcium-handling protein expression (SERCA2a, phospholamban), reduced markers of cardiomyocyte apoptosis after ischaemic stress, improved contractile metrics in animal models, and restoration of cardiac antioxidant enzymes (SOD, catalase, glutathione peroxidase) toward younger baselines. Some Russian-language work also reports improved endothelial nitric-oxide signalling. Almost all of the evidence is from the originating institute and has not been independently replicated.

Published Safety Data

What the published studies measured.

What the studies show
Measured in clinical trials
  • Russian clinical and preclinical literature reports essentially no significant adverse events at the studied exposures. The Khavinson cardiology cohorts (5-10 mg/day for 10-20 day courses repeated biannually in elderly post-MI and ischemic-heart-disease patients) noted no clinically meaningful side effects across the published series.
  • Injection site reactions: mild redness, transient soreness, or warmth, the most common observable effect, resolves within hours.
  • No documented changes in liver enzymes, kidney markers, or hematological parameters across the published Russian cohorts.
  • No documented arrhythmic, hypotensive, or bradycardic events in the Khavinson cardiology cohort reports. The peptide does not have direct cardiac-receptor agonist or antagonist activity, so it does not produce the acute hemodynamic effects of beta-blockers, calcium channel blockers, or other cardiac medications.
  • Allergic / hypersensitivity reactions: theoretically possible with any peptide, lower than for biological extracts because Cardiogen is a defined four-amino-acid synthetic rather than an extracted polypeptide complex; no consistent allergic signal in the published literature.
  • Western RCT data is absent. The evidence base is Russian-language Khavinson group publications plus animal model studies. Methodological standards differ from FDA-style trials (smaller cohorts, open-label, longer follow-up windows, gene-expression and clinical-symptom endpoints rather than mortality-powered RCTs).
The Research

Peer-reviewed studies and clinical guidelines — tap any to read the source.

PubMedKhavinson VK, Malinin VV — Gerontological aspects of genome peptide regulation, Karger Monograph 2005

foundational text on the Khavinson tissue-specific short-peptide bioregulator paradigm including the cardiac peptide family

Read study ↗
PubMedKhavinson VK — Peptides and Ageing, Neuro Endocrinol Lett 2002 vol 23 suppl 3

foundational review of the Khavinson short-peptide longevity program including Cardiogen

Read study ↗
PubMedKhavinson VK, Lin'kova NS, Tarnovskaya SI — Short peptides regulate gene expression, Bull Exp Biol Med 2016

Khavinson short peptides including the cardiac tetrapeptide regulate target gene expression in tissue-specific cell populations

Read study ↗
PubMedKhavinson VK, Kuznik BI, Tarnovskaya SI, Lin'kova NS — Peptides and CCL11 and HMGB1 as molecular markers of aging: literature review and own data, Adv Gerontol 2014

Khavinson cardiac and other tissue-specific short peptides in aging biomarker context

Read study ↗
PubMedAnisimov VN, Khavinson VK — Peptide bioregulation of aging: results and prospects, Biogerontology 2010

comprehensive review of the Khavinson peptide bioregulator program including cardiac peptide cohort outcomes

Read study ↗
PubMedKhavinson VK, Morozov VG — Peptides of pineal gland and thymus prolong human life, Neuro Endocrinol Lett 2003

12-year follow-up Khavinson elderly cohort, 1.6-1.8x mortality reduction with biannual bioregulator pulses, includes cardiac context

Read study ↗
+ 6 more studies & references

Reconstitution & Storage

Storage: refrigerated, ~28 days after reconstitution. Lyophilized vials store at room temp short-term, refrigerate or freeze for longer hold. The AEDR tetrapeptide is reasonably stable as a defined small synthetic; the 10-day pulse falls well inside the 28-day reconstituted window.

All products sold for research purposes only. Not for human or animal consumption. Must be 18+ to purchase. By placing an order you confirm compliance with all applicable local laws and regulations.